O	O	0	6	Potent	Potent	B-NP	JJ	O	2	NMOD	O
O	O	7	17	inhibition	inhibition	I-NP	NN	O	0	ROOT	O
O	O	18	20	of	of	B-PP	IN	O	2	NMOD	O
O	O	21	24	HIV	HIV	B-NP	NN	O	7	NMOD	O
O	O	25	29	type	type	I-NP	NN	O	7	NMOD	O
O	O	30	31	1	1	I-NP	CD	O	7	NMOD	O
O	O	32	43	replication	replication	I-NP	NN	O	3	PMOD	O
O	O	44	46	by	by	B-PP	IN	O	2	NMOD	O
O	O	47	49	an	an	B-NP	DT	O	11	NMOD	O
O	O	50	66	antiinflammatory	antiinflammatory	I-NP	JJ	O	11	NMOD	O
O	O	67	75	alkaloid	alkaloid	I-NP	NN	O	13	NMOD	O
O	O	75	76	,	,	O	,	O	13	P	O
O	O	77	90	cepharanthine	cepharanthine	B-NP	NN	O	8	PMOD	O
O	O	90	91	,	,	O	,	O	2	P	O
O	O	92	94	in	in	B-PP	IN	O	2	NMOD	O
O	O	95	106	chronically	chronically	B-NP	RB	B-cell_type	19	NMOD	B-cell_type
O	O	107	115	infected	infected	I-NP	JJ	I-cell_type	19	NMOD	I-cell_type
O	O	116	125	monocytic	monocytic	I-NP	JJ	I-cell_type	19	NMOD	I-cell_type
O	O	126	131	cells	cell	I-NP	NNS	I-cell_type	15	PMOD	I-cell_type
O	O	131	132	.	.	O	.	O	2	P	O

O	O	134	147	Cepharanthine	Cepharanthine	B-NP	NN	O	2	SUB	O
O	O	148	150	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	151	152	a	a	B-NP	DT	O	5	NMOD	O
O	O	153	166	biscoclaurine	biscoclaurine	I-NP	NN	O	5	NMOD	O
O	O	167	175	alkaloid	alkaloid	I-NP	NN	O	2	PRD	O
O	O	176	184	isolated	isolate	B-VP	VBN	O	5	NMOD	O
O	O	185	189	from	from	B-PP	IN	O	6	VMOD	O
O	O	190	199	Stephania	Stephania	B-NP	NNP	O	10	NMOD	O
O	O	200	211	cepharantha	cepharantha	I-NP	NN	O	10	NMOD	O
O	O	212	218	Hayata	Hayata	I-NP	NNP	O	7	PMOD	O
O	O	219	222	and	and	O	CC	O	2	VMOD	O
O	O	223	226	has	have	B-VP	VBZ	O	2	VMOD	O
O	O	227	231	been	be	I-VP	VBN	O	12	VC	O
O	O	232	237	shown	show	I-VP	VBN	O	13	VC	O
O	O	238	240	to	to	I-VP	TO	O	16	VMOD	O
O	O	241	245	have	have	I-VP	VB	O	14	VMOD	O
O	O	246	262	antiinflammatory	antiinflammatory	B-NP	JJ	O	23	NMOD	O
O	O	262	263	,	,	I-NP	,	O	23	P	O
O	O	264	276	antiallergic	antiallergic	I-NP	JJ	O	23	NMOD	O
O	O	276	277	,	,	O	,	O	23	P	O
O	O	278	281	and	and	O	CC	O	23	NMOD	O
O	O	282	298	immunomodulatory	immunomodulatory	B-NP	JJ	O	23	NMOD	O
O	O	299	309	activities	activity	I-NP	NNS	O	16	OBJ	O
O	O	310	312	in	in	B-ADVP	FW	O	16	VMOD	O
O	O	313	317	vivo	vivo	I-ADVP	FW	O	24	AMOD	O
O	O	317	318	.	.	O	.	O	2	P	O

O	O	319	321	As	As	B-SBAR	IN	O	20	VMOD	O
O	O	322	329	several	several	B-NP	JJ	O	7	NMOD	O
O	O	330	342	inflammatory	inflammatory	I-NP	JJ	B-protein	4	NMOD	B-protein
O	O	343	352	cytokines	cytokine	I-NP	NNS	I-protein	2	NMOD	I-protein
O	O	353	356	and	and	O	CC	O	2	NMOD	O
O	O	357	366	oxidative	oxidative	B-NP	JJ	O	2	NMOD	O
O	O	367	375	stresses	stress	I-NP	NNS	O	8	SUB	O
O	O	376	379	are	be	B-VP	VBP	O	1	SBAR	O
O	O	380	388	involved	involve	I-VP	VBN	O	8	VC	O
O	O	389	391	in	in	B-PP	IN	O	9	VMOD	O
O	O	392	395	the	the	B-NP	DT	O	12	NMOD	O
O	O	396	408	pathogenesis	pathogenesis	I-NP	NN	O	10	PMOD	O
O	O	409	411	of	of	B-PP	IN	O	12	NMOD	O
O	O	412	415	HIV	HIV	B-NP	NN	O	17	NMOD	O
O	O	415	416	-	-	B-NP	HYPH	O	17	NMOD	O
O	O	416	417	1	1	I-NP	CD	O	17	NMOD	O
O	O	418	427	infection	infection	I-NP	NN	O	13	PMOD	O
O	O	427	428	,	,	O	,	O	20	P	O
O	O	429	431	we	we	B-NP	PRP	O	20	SUB	O
O	O	432	444	investigated	investigate	B-VP	VBD	O	0	ROOT	O
O	O	445	448	the	the	B-NP	DT	O	23	NMOD	O
O	O	449	459	inhibitory	inhibitory	I-NP	JJ	O	23	NMOD	O
O	O	460	467	effects	effect	I-NP	NNS	O	20	OBJ	O
O	O	468	470	of	of	B-PP	IN	O	23	NMOD	O
O	O	471	484	cepharanthine	cepharanthine	B-NP	NN	O	24	PMOD	O
O	O	485	487	on	on	B-PP	IN	O	23	NMOD	O
T1	B-Protein	488	493	tumor	tumor	B-NP	NN	B-protein	30	NMOD	B-protein
T1	I-Protein	494	502	necrosis	necrosis	I-NP	NN	I-protein	30	NMOD	I-protein
T1	I-Protein	503	509	factor	factor	I-NP	NN	I-protein	30	NMOD	I-protein
T1	I-Protein	510	515	alpha	alpha	I-NP	NN	I-protein	34	NMOD	I-protein
O	O	516	517	(	(	O	(	O	34	NMOD	O
T2	B-Protein	517	520	TNF	TNF	B-NP	NN	B-protein	34	NMOD	B-protein
T2	I-Protein	520	521	-	-	O	HYPH	O	34	P	O
T2	I-Protein	521	526	alpha	alpha	B-NP	SYM	O	44	NMOD	O
O	O	526	527	)	)	O	)	O	34	NMOD	O
O	O	527	528	-	-	O	HYPH	O	34	P	O
O	O	529	532	and	and	O	CC	O	44	NMOD	O
O	O	533	540	phorbol	phorbol	B-NP	NN	O	44	NMOD	O
O	O	541	543	12	12	I-NP	CD	O	38	NMOD	O
O	O	543	544	-	-	O	HYPH	O	44	NMOD	O
O	O	544	553	myristate	myristate	B-NP	NN	B-protein	44	NMOD	B-protein
O	O	554	556	13	13	I-NP	CD	I-protein	41	NMOD	I-protein
O	O	556	557	-	-	O	HYPH	O	41	P	O
O	O	557	564	acetate	acetate	B-NP	NN	O	53	NMOD	O
O	O	565	566	(	(	O	(	O	47	DEP	O
O	O	566	569	PMA	PMA	B-NP	NN	O	47	DEP	O
O	O	569	570	)	)	O	)	O	44	NMOD	O
O	O	570	571	-	-	O	HYPH	O	44	P	O
O	O	571	578	induced	induce	B-NP	VBN	O	53	NMOD	O
O	O	579	582	HIV	HIV	I-NP	NN	O	53	NMOD	O
O	O	582	583	-	-	B-NP	HYPH	O	53	NMOD	O
O	O	583	584	1	1	I-NP	CD	O	53	NMOD	O
O	O	585	596	replication	replication	I-NP	NN	O	26	PMOD	O
O	O	597	599	in	in	B-PP	IN	O	53	NMOD	O
O	O	600	611	chronically	chronically	B-NP	RB	B-cell_line	56	AMOD	B-cell_line
O	O	612	620	infected	infected	I-NP	JJ	I-cell_line	58	NMOD	I-cell_line
O	O	621	625	cell	cell	I-NP	NN	I-cell_line	58	NMOD	I-cell_line
O	O	626	631	lines	line	I-NP	NNS	I-cell_line	54	PMOD	I-cell_line
O	O	631	632	.	.	O	.	O	20	P	O

O	O	633	636	Two	Two	B-NP	CD	O	9	NMOD	O
O	O	637	648	chronically	chronically	I-NP	RB	B-cell_line	9	NMOD	B-cell_line
O	O	649	652	HIV	HIV	I-NP	NN	I-cell_line	9	NMOD	I-cell_line
O	O	652	653	-	-	B-NP	HYPH	I-cell_line	9	NMOD	I-cell_line
O	O	653	654	1	1	I-NP	CD	I-cell_line	9	NMOD	I-cell_line
O	O	654	655	-	-	I-NP	HYPH	I-cell_line	9	NMOD	I-cell_line
O	O	655	663	infected	infect	I-NP	VBN	I-cell_line	9	NMOD	I-cell_line
O	O	664	668	cell	cell	I-NP	NN	I-cell_line	9	NMOD	I-cell_line
O	O	669	674	lines	line	I-NP	NNS	I-cell_line	11	NMOD	I-cell_line
O	O	674	675	,	,	O	,	O	11	P	O
O	O	676	678	U1	U1	B-NP	NN	B-cell_line	24	SUB	B-cell_line
O	O	679	680	(	(	O	(	O	14	DEP	O
O	O	680	689	monocytic	monocytic	B-ADJP	JJ	O	14	DEP	O
O	O	689	690	)	)	O	)	O	11	NMOD	O
O	O	691	694	and	and	O	CC	O	24	VMOD	O
O	O	695	698	ACH	ACH	B-NP	NN	B-protein	24	SUB	B-protein
O	O	698	699	-	-	O	HYPH	I-protein	16	NMOD	I-protein
O	O	699	700	2	2	B-NP	CD	I-protein	16	NMOD	I-protein
O	O	701	702	(	(	O	(	O	22	DEP	O
O	O	702	703	T	T	B-NP	NN	O	22	DEP	O
O	O	704	715	lymphocytic	lymphocytic	B-ADJP	JJ	O	20	NMOD	O
O	O	715	716	)	)	O	)	O	16	NMOD	O
O	O	716	717	,	,	O	,	O	16	P	O
O	O	718	722	were	be	B-VP	VBD	O	0	ROOT	O
O	O	723	733	stimulated	stimulate	I-VP	VBN	O	24	VC	O
O	O	734	738	with	with	B-PP	IN	O	25	VMOD	O
T3	B-Protein	739	742	TNF	TNF	B-NP	NN	B-protein	29	NMOD	B-protein
T3	I-Protein	742	743	-	-	O	HYPH	O	29	P	O
T3	I-Protein	743	748	alpha	alpha	B-NP	SYM	O	31	NMOD	O
O	O	749	751	or	or	O	CC	O	31	NMOD	O
O	O	752	755	PMA	PMA	B-NP	NN	O	26	PMOD	O
O	O	756	759	and	and	O	CC	O	25	VMOD	O
O	O	760	768	cultured	culture	B-VP	VBN	O	25	VMOD	O
O	O	769	771	in	in	B-PP	IN	O	33	VMOD	O
O	O	772	775	the	the	B-NP	DT	O	36	NMOD	O
O	O	776	784	presence	presence	I-NP	NN	O	34	PMOD	O
O	O	785	787	of	of	B-PP	IN	O	36	NMOD	O
O	O	788	795	various	various	B-NP	JJ	O	39	NMOD	O
O	O	796	810	concentrations	concentration	I-NP	NNS	O	37	PMOD	O
O	O	811	813	of	of	B-PP	IN	O	39	NMOD	O
O	O	814	817	the	the	B-NP	DT	O	42	NMOD	O
O	O	818	826	compound	compound	I-NP	NN	O	40	PMOD	O
O	O	826	827	.	.	O	.	O	24	P	O

O	O	828	831	HIV	HIV	B-NP	NN	O	4	NMOD	O
O	O	831	832	-	-	B-NP	HYPH	O	4	NMOD	O
O	O	832	833	1	1	I-NP	CD	O	4	NMOD	O
O	O	834	845	replication	replication	I-NP	NN	O	5	SUB	O
O	O	846	849	was	be	B-VP	VBD	O	0	ROOT	O
O	O	850	860	determined	determine	I-VP	VBN	O	5	VC	O
O	O	861	863	by	by	B-PP	IN	O	6	VMOD	O
T4	B-Protein	864	867	p24	p24	B-NP	NN	B-protein	9	NMOD	B-protein
T4	I-Protein	868	875	antigen	antigen	I-NP	NN	I-protein	10	NMOD	I-protein
O	O	876	881	level	level	I-NP	NN	O	7	PMOD	O
O	O	881	882	.	.	O	.	O	5	P	O

O	O	883	886	The	The	B-NP	DT	O	3	NMOD	O
O	O	887	897	inhibitory	inhibitory	I-NP	JJ	O	3	NMOD	O
O	O	898	905	effects	effect	I-NP	NNS	O	30	SUB	O
O	O	906	908	of	of	B-PP	IN	O	3	NMOD	O
O	O	909	922	cepharanthine	cepharanthine	B-NP	NN	O	4	PMOD	O
O	O	923	925	on	on	B-PP	IN	O	3	NMOD	O
T6	B-Entity	926	929	HIV	HIV	B-NP	NN	B-DNA	12	NMOD	B-DNA
T6	I-Entity	929	930	-	-	B-NP	HYPH	I-DNA	12	NMOD	I-DNA
T6	I-Entity	930	931	1	1	I-NP	CD	I-DNA	12	NMOD	I-DNA
T6	I-Entity	932	936	long	long	I-NP	JJ	I-DNA	12	NMOD	I-DNA
T6	I-Entity	937	945	terminal	terminal	I-NP	JJ	I-DNA	12	NMOD	I-DNA
T6	I-Entity	946	952	repeat	repeat	I-NP	NN	I-DNA	19	NMOD	I-DNA
O	O	953	954	(	(	O	(	O	15	DEP	O
T7	B-Entity	954	957	LTR	LTR	B-NP	NN	B-DNA	15	DEP	B-DNA
O	O	957	958	)	)	O	)	O	12	NMOD	O
O	O	958	959	-	-	B-NP	HYPH	O	19	NMOD	O
O	O	959	965	driven	drive	I-NP	VBN	O	19	NMOD	O
O	O	966	970	gene	gene	I-NP	NN	O	19	NMOD	O
O	O	971	981	expression	expression	I-NP	NN	O	23	NMOD	O
O	O	982	985	and	and	O	CC	O	23	NMOD	O
O	O	986	993	nuclear	nuclear	B-NP	JJ	B-protein	23	NMOD	B-protein
O	O	994	1000	factor	factor	I-NP	NN	I-protein	23	NMOD	I-protein
O	O	1001	1007	kappaB	kappaB	I-NP	NN	I-protein	29	NMOD	I-protein
O	O	1008	1009	(	(	O	(	O	28	DEP	O
O	O	1009	1011	NF	NF	B-NP	NN	B-protein	27	NMOD	B-protein
O	O	1011	1012	-	-	B-NP	HYPH	I-protein	27	NMOD	I-protein
O	O	1012	1018	kappaB	kappaB	I-NP	NN	I-protein	28	DEP	I-protein
O	O	1018	1019	)	)	O	)	O	23	NMOD	O
T8	B-Entity	1020	1030	activation	activation	B-NP	NN	O	6	PMOD	O
O	O	1031	1035	were	be	B-VP	VBD	O	0	ROOT	O
O	O	1036	1040	also	also	I-VP	RB	O	30	VMOD	O
O	O	1041	1049	examined	examine	I-VP	VBN	O	30	VC	O
O	O	1049	1050	.	.	O	.	O	30	P	O

O	O	1051	1064	Cepharanthine	Cepharanthine	B-NP	NN	O	2	NMOD	O
O	O	1065	1069	dose	dose	I-NP	NN	O	4	SUB	O
O	O	1070	1081	dependently	dependently	B-ADVP	RB	O	4	VMOD	O
O	O	1082	1091	inhibited	inhibit	B-VP	VBD	O	0	ROOT	O
O	O	1092	1095	HIV	HIV	B-NP	NN	O	8	NMOD	O
O	O	1095	1096	-	-	B-NP	HYPH	O	8	NMOD	O
O	O	1096	1097	1	1	I-NP	CD	O	8	NMOD	O
O	O	1098	1109	replication	replication	I-NP	NN	O	4	OBJ	O
O	O	1110	1112	in	in	B-PP	IN	O	8	NMOD	O
T5	B-Protein	1113	1116	TNF	TNF	B-NP	NN	B-protein	19	NMOD	B-protein
T5	I-Protein	1116	1117	-	-	B-NP	HYPH	O	19	P	O
T5	I-Protein	1117	1122	alpha	alpha	I-NP	SYM	O	19	NMOD	O
O	O	1122	1123	-	-	I-NP	HYPH	O	12	P	O
O	O	1124	1127	and	and	I-NP	CC	O	12	AMOD	O
O	O	1128	1131	PMA	PMA	I-NP	NN	O	19	NMOD	O
O	O	1131	1132	-	-	I-NP	HYPH	O	19	P	O
O	O	1132	1142	stimulated	stimulate	I-NP	VBN	O	19	NMOD	O
O	O	1143	1145	U1	U1	I-NP	NN	B-cell_line	19	NMOD	B-cell_line
O	O	1146	1151	cells	cell	I-NP	NNS	I-cell_line	9	PMOD	I-cell_line
O	O	1152	1155	but	but	B-PP	CC	O	9	PMOD	O
O	O	1156	1159	not	not	B-PP	RB	O	22	PMOD	O
O	O	1160	1162	in	in	I-PP	IN	O	9	PMOD	O
O	O	1163	1166	ACH	ACH	B-NP	NN	B-cell_line	26	NMOD	B-cell_line
O	O	1166	1167	-	-	B-NP	HYPH	I-cell_line	26	NMOD	I-cell_line
O	O	1167	1168	2	2	I-NP	CD	I-cell_line	26	NMOD	I-cell_line
O	O	1169	1174	cells	cell	I-NP	NNS	I-cell_line	22	PMOD	I-cell_line
O	O	1174	1175	.	.	O	.	O	4	P	O

O	O	1176	1179	Its	Its	B-NP	PRP$	O	7	NMOD	O
O	O	1180	1182	50	50	I-NP	CD	O	3	AMOD	O
O	O	1182	1183	%	%	I-NP	NN	O	7	NMOD	O
O	O	1184	1193	effective	effective	B-ADJP	JJ	O	7	NMOD	O
O	O	1194	1197	and	and	O	CC	O	7	NMOD	O
O	O	1198	1207	cytotoxic	cytotoxic	B-NP	JJ	O	7	NMOD	O
O	O	1208	1222	concentrations	concentration	I-NP	NNS	O	8	SUB	O
O	O	1223	1227	were	be	B-VP	VBD	O	0	ROOT	O
O	O	1228	1229	0	0	B-NP	CD	O	18	NMOD	O
O	O	1229	1230	.	.	O	.	O	18	NMOD	O
O	O	1230	1233	016	016	B-NP	CD	B-DNA	13	NMOD	B-DNA
O	O	1234	1237	and	and	I-NP	CC	I-DNA	13	NMOD	I-DNA
O	O	1238	1239	2	2	I-NP	CD	I-DNA	18	NMOD	I-DNA
O	O	1239	1240	.	.	O	.	O	18	NMOD	O
O	O	1240	1241	2	2	B-NP	CD	O	18	NMOD	O
O	O	1242	1248	microg	microg	I-NP	NN	O	18	NMOD	O
O	O	1248	1249	/	/	B-NP	SYM	O	18	NMOD	O
O	O	1249	1251	ml	ml	I-NP	NN	O	8	PRD	O
O	O	1252	1254	in	in	B-PP	IN	O	18	NMOD	O
O	O	1255	1258	PMA	PMA	B-NP	NN	B-cell_line	24	NMOD	B-cell_line
O	O	1258	1259	-	-	B-NP	HYPH	I-cell_line	24	NMOD	I-cell_line
O	O	1259	1269	stimulated	stimulate	I-NP	VBN	I-cell_line	24	NMOD	I-cell_line
O	O	1270	1272	U1	U1	I-NP	NN	I-cell_line	24	NMOD	I-cell_line
O	O	1273	1278	cells	cell	I-NP	NNS	I-cell_line	19	PMOD	I-cell_line
O	O	1278	1279	,	,	O	,	O	18	P	O
O	O	1280	1292	respectively	respectively	B-ADVP	RB	O	18	NMOD	O
O	O	1292	1293	.	.	O	.	O	8	P	O

O	O	1294	1307	Cepharanthine	Cepharanthine	B-NP	NN	O	2	SUB	O
O	O	1308	1311	was	be	B-VP	VBD	O	0	ROOT	O
O	O	1312	1317	found	find	I-VP	VBN	O	2	VC	O
O	O	1318	1320	to	to	I-VP	TO	O	5	VMOD	O
O	O	1321	1329	suppress	suppress	I-VP	VB	O	3	VMOD	O
T9	B-Entity	1330	1333	HIV	HIV	B-NP	NN	B-DNA	9	NMOD	B-DNA
T9	I-Entity	1333	1334	-	-	O	HYPH	I-DNA	9	P	I-DNA
T9	I-Entity	1334	1335	1	1	B-NP	CD	I-DNA	9	NMOD	I-DNA
T9	I-Entity	1336	1339	LTR	LTR	I-NP	NN	I-DNA	13	NMOD	I-DNA
O	O	1339	1340	-	-	B-NP	HYPH	O	9	P	O
O	O	1340	1346	driven	drive	I-NP	VBN	O	9	AMOD	O
O	O	1347	1351	gene	gene	I-NP	NN	O	13	NMOD	O
O	O	1352	1362	expression	expression	I-NP	NN	O	5	OBJ	O
O	O	1363	1370	through	through	B-PP	IN	O	13	NMOD	O
O	O	1371	1374	the	the	B-NP	DT	O	16	NMOD	O
O	O	1375	1385	inhibition	inhibition	I-NP	NN	O	14	PMOD	O
O	O	1386	1388	of	of	B-PP	IN	O	16	NMOD	O
T10	B-Entity	1389	1391	NF	NF	B-NP	NN	B-protein	20	NMOD	B-protein
T10	I-Entity	1391	1392	-	-	B-NP	HYPH	I-protein	20	NMOD	I-protein
T10	I-Entity	1392	1398	kappaB	kappaB	I-NP	NN	I-protein	21	NMOD	I-protein
O	O	1399	1409	activation	activation	I-NP	NN	O	17	PMOD	O
O	O	1409	1410	.	.	O	.	O	2	P	O

O	O	1411	1416	These	These	B-NP	DT	O	2	NMOD	O
O	O	1417	1424	results	result	I-NP	NNS	O	3	SUB	O
O	O	1425	1433	indicate	indicate	B-VP	VBP	O	0	ROOT	O
O	O	1434	1438	that	that	B-SBAR	IN	O	3	VMOD	O
O	O	1439	1452	cepharanthine	cepharanthine	B-NP	NN	O	6	SUB	O
O	O	1453	1455	is	be	B-VP	VBZ	O	4	SBAR	O
O	O	1456	1457	a	a	B-NP	DT	O	10	NMOD	O
O	O	1458	1464	highly	highly	I-NP	RB	O	9	AMOD	O
O	O	1465	1471	potent	potent	I-NP	JJ	O	10	NMOD	O
O	O	1472	1481	inhibitor	inhibitor	I-NP	NN	O	15	NMOD	O
O	O	1482	1484	of	of	B-PP	IN	O	10	NMOD	O
O	O	1485	1488	HIV	HIV	B-NP	NN	O	11	PMOD	O
O	O	1488	1489	-	-	B-NP	HYPH	O	15	NMOD	O
O	O	1489	1490	1	1	I-NP	CD	O	15	NMOD	O
O	O	1491	1502	replication	replication	I-NP	NN	O	6	PRD	O
O	O	1503	1505	in	in	B-PP	IN	O	15	NMOD	O
O	O	1506	1507	a	a	B-NP	DT	O	22	NMOD	O
O	O	1508	1519	chronically	chronically	I-NP	RB	B-cell_line	22	NMOD	B-cell_line
O	O	1520	1528	infected	infected	I-NP	JJ	I-cell_line	22	NMOD	I-cell_line
O	O	1529	1538	monocytic	monocytic	I-NP	JJ	I-cell_line	22	NMOD	I-cell_line
O	O	1539	1543	cell	cell	I-NP	NN	I-cell_line	22	NMOD	I-cell_line
O	O	1544	1548	line	line	I-NP	NN	I-cell_line	16	PMOD	I-cell_line
O	O	1548	1549	.	.	O	.	O	3	P	O

O	O	1550	1555	Since	Since	B-SBAR	IN	O	12	VMOD	O
O	O	1556	1569	biscoclaurine	biscoclaurine	B-NP	NN	O	3	NMOD	O
O	O	1570	1579	alkaloids	alkaloid	I-NP	NNS	O	1	PMOD	O
O	O	1579	1580	,	,	O	,	O	3	P	O
O	O	1581	1591	containing	contain	B-VP	VBG	O	3	NMOD	O
O	O	1592	1605	cepharanthine	cepharanthine	B-NP	NN	O	5	OBJ	O
O	O	1606	1608	as	as	B-PP	IN	O	5	VMOD	O
O	O	1609	1610	a	a	B-NP	DT	O	10	NMOD	O
O	O	1611	1616	major	major	I-NP	JJ	O	10	NMOD	O
O	O	1617	1626	component	component	I-NP	NN	O	7	PMOD	O
O	O	1626	1627	,	,	O	,	O	12	P	O
O	O	1628	1631	are	be	B-VP	VBP	O	28	VMOD	O
O	O	1632	1638	widely	widely	I-VP	RB	O	12	VMOD	O
O	O	1639	1643	used	use	I-VP	VBN	O	12	VC	O
O	O	1644	1647	for	for	B-PP	IN	O	14	VMOD	O
O	O	1648	1651	the	the	B-NP	DT	O	17	NMOD	O
O	O	1652	1661	treatment	treatment	I-NP	NN	O	15	PMOD	O
O	O	1662	1664	of	of	B-PP	IN	O	17	NMOD	O
O	O	1665	1673	patients	patient	B-NP	NNS	O	18	PMOD	O
O	O	1674	1678	with	with	B-PP	IN	O	19	NMOD	O
O	O	1679	1686	various	various	B-NP	JJ	O	23	NMOD	O
O	O	1687	1699	inflammatory	inflammatory	I-NP	JJ	O	23	NMOD	O
O	O	1700	1708	diseases	disease	I-NP	NNS	O	20	PMOD	O
O	O	1709	1711	in	in	B-PP	IN	O	17	NMOD	O
O	O	1712	1717	Japan	Japan	B-NP	NNP	O	24	PMOD	O
O	O	1717	1718	,	,	O	,	O	12	P	O
O	O	1719	1732	cepharanthine	cepharanthine	B-NP	NN	O	28	SUB	O
O	O	1733	1739	should	should	B-VP	MD	O	0	ROOT	O
O	O	1740	1742	be	be	I-VP	VB	O	28	VC	O
O	O	1743	1750	further	further	B-ADJP	RBR	O	29	VMOD	O
O	O	1751	1758	pursued	pursue	I-ADJP	VBN	O	29	VC	O
O	O	1759	1762	for	for	B-PP	IN	O	31	VMOD	O
O	O	1763	1766	its	its	B-NP	PRP$	O	35	NMOD	O
O	O	1767	1783	chemotherapeutic	chemotherapeutic	I-NP	JJ	O	35	NMOD	O
O	O	1784	1793	potential	potential	I-NP	NN	O	32	PMOD	O
O	O	1794	1796	in	in	B-PP	IN	O	35	NMOD	O
O	O	1797	1800	HIV	HIV	B-NP	NN	O	42	NMOD	O
O	O	1800	1801	-	-	B-NP	HYPH	O	42	NMOD	O
O	O	1801	1802	1	1	I-NP	CD	O	42	NMOD	O
O	O	1802	1803	-	-	B-NP	HYPH	O	42	NMOD	O
O	O	1803	1811	infected	infect	I-NP	VBN	O	42	NMOD	O
O	O	1812	1820	patients	patient	I-NP	NNS	O	36	PMOD	O
O	O	1820	1821	.	.	O	.	O	28	P	O
